Summary
The rate of initial detection of breast tumours varies during the year in a seasonal fashion, more tumours being discovered in late spring/early summer than at other times of the year. This phenomenon is particularly pronounced in young women (< 50 years) with progesterone receptor positive tumours. The present study investigates whether season of tumour detection influences the predictive capacity of several recognised prognostic and risk factors in patients with breast cancer. Axillary nodal status, tumour progesterone receptor status, and season of tumour detection significantly influenced survival in both older (> 50 yrs) and younger (< 50 yrs) patients. Parity, lactational history, body mass index, tumour oestrogen receptor status, and patient age also influenced survival, but these effects were significant only in age groups < 50 or > 50 yrs. Season of detection of tumour did not affect the prognostic significance of axillary nodal status. However, the effect of oestrogen receptor status on survival was more significant in patients who detected their tumours in the spring/summer compared with winter (odds ratio 0.52 and 0.73 respectively). Negative progesterone receptor status was associated with significantly poorer survival only in patients with tumours found in the winter. There was a significant survival disadvantage for nulliparous compared with parous women with breast cancer who were ≥ 50 years at diagnosis, and for women who had never lactated compared with those who had lactated, but this disadvantage was restricted to those who found their tumours in the summer. An increased body mass index (≥ 28) was associated with decreased survival, but this was significant only for those detecting tumours in winter. The increased incidence of detection of breast cancer in spring/summer may reflect cyclic influences on tumour growth. Such influences may be hormonal in nature and may underlie the effect of season of tumour detection on the prognostic influence of lactation, parity, body mass index, and oestrogen and progesterone receptor status in patients with breast cancer.
References
Lee JAH: Seasonal alterations and the natural history of malignant neoplasms. Prog Clin Cancer 3: 96–106, 1967
Jacobsen HK, Janerich DT: (Abstract) Seasonal variation in the diagnosis of breast cancer. Proc Am Assoc Cancer Res 18: 93, 1977
Cohen P, Wax Y, Modan B: Seasonality in the occurrence of breast cancer. Cancer Res 43: 892–896, 1983
Hartveit F, Thoresen S, Tangen M, Halvorsen JF: Variation in histology and oestrogen receptor content in breast carcinoma related to tumour size and time of presentation. Clin Oncol 9: 233–238, 1983
Mason BH, Holdaway IM, Mullins PR, Kay RG, Skinner SJ: Seasonal variation in breast cancer detection: correlation with tumour progesterone receptor status. Breast Cancer Res Treat 5: 171–176, 1985
Kirkham N, Machin D, Cotton DWK, Pike JM: Seasonality and breast cancer. Europ J Surg Oncol 11: 143–146, 1985
Cohen P: (Abstract) Breast cancer prognosis and detection of the first symptom. Breast Cancer Res Treat 3: 311, 1983
Mason BH, Holdaway IM, Kay RG, Stewart AW, Skinner SJ: Abstract Season of breast cancer detection and disease progression. NZ Med J 101: 268, 1988
Hawkins RA, Roberts MM, Forrest APM: Oestrogen receptors and breast cancer: current status. Br J Surg 67: 153–169, 1980
Fagnart OC, Cambiaso CL, Lejeune MD, Noel G, Maisin H, Masson PL: Prognostic value of concentration of pregnancy-specific beta 1-glycoprotein in serum of patients with breast cancer. Int J Cancer 36: 541–544, 1985
McGuire WL: Prognostic factors in primary breast cancer. Cancer Surv 5: 527–536, 1986
Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL: DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61: 420–427, 1988
Sainsbury JRC, Farndon JR, Needham GK, Malcolm AJ, Harris AL: Epidermal growth factor status as predictor of early recurrence and death from breast cancer. Lancet 1: 1398–1402, 1987
McNee RK, Mason BH, Neave LM, Kay RG: Influence of height, weight, and obesity on breast cancer incidence and recurrence in Auckland, New Zealand. Breast Cancer Res Treat 9: 145–150, 1987
Greenberg ER, Vessey MP, McPherson K, Doll R, Yeates D: Body size and survival in premenopausal breast cancer. Br J Cancer 51: 691–697, 1985
Dowsett M, McGarrick GE, Harris AL, Coombes RC, Smith IE, Jeffcoate SL: Prognostic significance of serum prolactin levels in advanced breast cancer. Br J Cancer 47: 763–769, 1983
Waseda N, Kato Y, Imura H, Kurata M: Prognostic value of oestrogen and prolactin receptor analysis in human breast cancer. Jpn J Cancer Res 76: 517–523, 1985
Bonneterre J, Peyrat JP, Beuscart R, Lefebvre J, Demaille A: Prognostic significance of prolactin receptors in human breast cancer. Cancer Res 47: 4724–4728, 1987
Adami HO, Malker B, Holmberg L, Persson I, Stone B: The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315: 559–563, 1986
H'st H, Lund E: Age as a prognostic factor in breast cancer. Cancer 47: 2217–2221, 1986
Mason BH, Holdaway IM, Skinner SJ, Stewart AW, Kay RG, Neave LM, Anderson J: Association between season of first detection ot breast cancer and disease progression. Breast Cancer Res Treat 9: 227–232, 1987
Holdaway IM: Principles of radioreceptor assays. In: Odell WD, Franchimont P (eds) Principles of Radioreceptor Assays. Wiley, New York, 1982, pp. 255–265
Cox RD: Regression models and life tables (with discussion). J Roy Stat Soc (B) 34: 182–220, 1972
Kennaway DJ, Gilmore TA, Seamark RF: Effect of melatonin feeding on serum prolactin and gonadotrophin levels and the onset of seasonal cyclicity in sheep. Endocrinology 110: 1766–1772, 1982
Wright J, Aldhous M, Franey C, English J, Arendt J: The effects of exogenous melatonin on endocrine function in man. Clin Endocrinol 24: 375–382, 1986
Touitou Y, Carayon A, Reinberg A, Bogdan A, Beck H: Differences in the seasonal rhythmicity of plasma prolactin in elderly human subjects: detection in women but not in men. J Endocrinol 96: 65–71, 1983
Haus E, Lakatua DJ, Halberg F, Halberg E, Cornelissen G, Sackett LL, Berg HG, Kawasaki T, Ueno M, Uezono K, Matsuoka M, Omae T: Chronobiological studies of plasma prolactin in women in Kyushu, Japan, and Minnesota, USA. J Clin Endocrinol Metab 51: 632–640, 1980
Wang DY, De Stavola BL, Bulbrook RD, Allen DS, Kwa HG, Gravelle IH: The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk — A population study of post-menopausal women. Europ J Cancer Clin Oncol 24: 1225–1231, 1988
Musey VC, Delwood C, Collins C, Musey PI, Martino-Saltzman MS, Preedy JRK: Long-term effect of a first pregnancy on the secretion of prolactin. New Engl J Med 316: 229–234, 1987
Brunning PF, Bonfrer JMG, Verstraeten AA: Prolactin levels after surgery (letter). N Engl J Med 6: 384–385, 1987
Yu MC, Gerkins VR, Henderson BE, Brown JB, Pike MC: Elevated levels of prolactin in nulliparous women. Br J Cancer 43: 826–831, 1981
Kwa HG, Bulbrook RD, Cleton F, Verstraeten AA, Hayward JL, Wang DY: An abnormal early evening peak of plasma prolactin in nulliparous and obese post-menopausal women. Int J Cancer 22: 691–693, 1978
Meyer F, Brown JB, Morrison AS, MacMahon B: Endogenous sex hormones, prolactin, and breast cancer in premenopausal women. J Nat Cancer Inst 77: 613–616, 1986
Englesman E, Heuson JC, Blonk-Van der Wijst J, Drochmans A, Maass H, Cheix F, Sobrinho LG, Nowakowski H: Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer, an EORTC study. Br Med J 2: 714–715, 1975
European Breast Cancer Group: Clinical trial of 2-Br-α-ergocryptine (CB154) in advanced breast cancer. Eur J Cancer 8: 155–156, 1972
Holdaway IM, Friesen HG: Hormone binding by human mammary carcinoma. Cancer Res 37: 1946–1951, 1977
Di Carlo R, Muccioli G: Prolactin receptor in human mammary carcinoma. Tumori 65: 695–702, 1979
Schindler AE, Ebert E, Friedreich E: Conversion of androstenedione to estrone by human fat tissue. J Clin Endocrinol Metab 5: 627–630, 1972
Onegan WL, Biedrzycki L: (Abstract) Obesity and oestrogen production in breast cancer patients. Cancer Treat Rep 63: 1204, 1979
Shultz TD, Wilcox RB, Spuehler JM, Howie BJ: Dietary and hormonal interrelationships in premenopausal women: evidence for a relationship between dietary nutrients and plasma prolactin levels. Am J Clin Nutr 46: 905–911, 1987
Van Staveren WA, Deurenberg P, Burema J, DeGroot LCPGM, Hautvast JGAJ: Seasonal variation in food intake, pattern of physical activity and change in body weight in a group of young adult Dutch women consuming self selected diets. Int J Obesity 10: 133–145, 1986
Gordon DJ, Hyde J, Trost DC, Whaley FS, Hannan PJ, Jacobs DR, Ekelund L: Cyclic seasonal variation in plasma lipid and lipoprotein levels: the Lipid Research Clinic's coronary primary prevention trial placebo group. J Clin Epidemiol 41: 679–689, 1988
Hrushesky W, Teslow T, Halberg F, Kiang D, Kennedy BJ: (Abstract) Temporal components of predictable variability along the 1-year scale in oestrogen receptor concentration of primary human breast cancer. ASCO 20 (C-165): 331, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mason, B.H., Holdaway, I.M., Stewart, A.W. et al. Season of tumour detection influences factors predicting survival of patients with breast cancer. Breast Cancer Res Tr 15, 27–37 (1990). https://doi.org/10.1007/BF01811887
Issue Date:
DOI: https://doi.org/10.1007/BF01811887